Author： Margolin Sara Lindh Jonatan D Thorén Linda Xie Hanjing Koukel Larissa Dahl Marja-Liisa Eliasson Erik
Publisher： Future Medicine
ISSN： 1462-2416
Source： Pharmacogenomics, Vol.14, Iss.6, 2013-04, pp. : 613-622
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content
Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment
By Walko Christine M McLeod Howard
Pharmacogenomics, Vol. 13, Iss. 6, 2012-04 ,pp. :
Access to resources
Recommend
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients
By van Schaik Ron HN Kok Marleen Sweep Fred CGJ van Vliet Martin van Fessem Marianne Meijer-van Gelder Marion E Seynaeve Caroline Lindemans Jan Wesseling Jelle Van ‘t Veer Laura J Span Paul N van Laarhoven Hanneke Sleijfer Stefan Foekens John A Linn Sabine C Berns Els MJJ
Pharmacogenomics, Vol. 12, Iss. 8, 2011-08 ,pp. :
Pharmacogenetics of Tamoxifen: Who Should Undergo
By Higgins Michaela J. Rae James M. Flockhart David A. Hayes Daniel F. Stearns Vered
Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 7, Iss. 2, 2009-02 ,pp. :
Cambridge Scholars Publishing in association with GSE Research
By Dandara Collet Mutowembwa Masimirembwa Collen Magimba Ayoub Sayi Jane Kaaya Sylvia Sommers De K. Snyman J.R. Hasler Julia Anne
European Journal of Clinical Pharmacology, Vol. 57, Iss. 1, 2001-04 ,pp. :
By Inanir A Özoran K Tutkak H Mermerci B
The Journal of International Medical Research, Vol. 32, Iss. 6, 2004-11 ,pp. :